Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 27, 2001

Primary Completion Date

March 17, 2005

Study Completion Date

August 15, 2006

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

imatinib mesylate

Trial Locations (11)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Comprehensive Cancer Center, Madison

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94143-0128

UCSF Comprehensive Cancer Center, San Francisco

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

48109-0316

University of Michigan Comprehensive Cancer Center, Ann Arbor

75390-9154

Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-6220

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00010049 - Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma | Biotech Hunter | Biotech Hunter